Skinvive by Juvederm FDA Approval History
Last updated by Judith Stewart, BPharm on May 30, 2023.
FDA Approved: Yes (First approved May 15, 2023)
Brand name: Skinvive by Juvederm
Generic name: hyaluronic acid and lidocaine
Dosage form: Injectable Gel
Company: AbbVie Inc.
Treatment for: Facial Wrinkles
Skinvive by Juvéderm (hyaluronic acid and lidocaine) is an intradermal microdroplet injection containing a dermal filler and a local anesthetic used to improve skin smoothness of the cheeks in adults over the age of 21.
- Skinvive by Juvéderm works to improve skin quality in the cheeks by smoothing the skin and increasing hydration.
- Hyaluronic acid is a naturally occurring substance in the body that helps to hydrate and add volume to the skin. It is chemically bonded to create a stable gel-like substance that can be injected under the skin to add volume, and smooth out wrinkles and fine lines.
- Skinvive by Juvéderm is a microdroplet injection, administered intradermally into the skin of the cheeks in volumes of 0.01 mL to 0.05 mL, and spaced approximately 0.5 cm to 1 cm apart.
- Skinvive by Juvéderm treatment should provide visible results for six months.
- Warnings and precautions associated with Skinvive by Juvéderm include unintentional injection into a blood vessel, which may cause embolization, occlusion of the vessels, ischemia, or infarction.
- Common adverse reactions include skin redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration and itching. Less common adverse reactions include inflammation, nodules, blood vessel blockage, infection, dry skin, increase or decrease in sensation, and abscess.
Development timeline for Skinvive by Juvederm
| Date | Article |
|---|---|
| May 15, 2023 | Approval FDA Approves Skinvive by Juvéderm (hyaluronic acid) Microdroplet Injection to Improve Skin Smoothness of the Cheeks |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
